Contineum Therapeutics (NASDAQ:CTNM – Get Free Report) was upgraded by equities research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Sunday.
Several other research analysts also recently commented on CTNM. Weiss Ratings restated a “sell (d-)” rating on shares of Contineum Therapeutics in a research note on Friday, July 17th. Royal Bank Of Canada upped their price target on Contineum Therapeutics from $22.00 to $23.00 and gave the company an “outperform” rating in a research report on Friday, July 31st. Finally, Morgan Stanley increased their price target on shares of Contineum Therapeutics from $14.00 to $16.00 and gave the stock an “equal weight” rating in a report on Thursday, May 14th. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Contineum Therapeutics has a consensus rating of “Hold” and an average target price of $20.25.
Read Our Latest Report on CTNM
Contineum Therapeutics Trading Down 3.3%
Contineum Therapeutics (NASDAQ:CTNM – Get Free Report) last posted its earnings results on Thursday, July 30th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.05. On average, equities research analysts forecast that Contineum Therapeutics will post -1.68 EPS for the current year.
Institutional Inflows and Outflows
A number of institutional investors have recently added to or reduced their stakes in CTNM. China Universal Asset Management Co. Ltd. bought a new stake in Contineum Therapeutics during the fourth quarter worth about $43,000. Strs Ohio purchased a new position in shares of Contineum Therapeutics during the 1st quarter valued at about $27,000. Royal Bank of Canada lifted its position in Contineum Therapeutics by 73.5% in the 1st quarter. Royal Bank of Canada now owns 5,794 shares of the company’s stock worth $76,000 after buying an additional 2,454 shares during the last quarter. California State Teachers Retirement System bought a new stake in Contineum Therapeutics in the 2nd quarter worth approximately $99,000. Finally, Bank of America Corp DE boosted its stake in Contineum Therapeutics by 500.0% in the third quarter. Bank of America Corp DE now owns 7,236 shares of the company’s stock worth $85,000 after buying an additional 6,030 shares in the last quarter.
About Contineum Therapeutics
Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist.
Featured Stories
- Five stocks we like better than Contineum Therapeutics
- Visa Just Put Hims & Hers in the Penalty Box—Here’s Why It Matters
- Treasury Yields Are Surging Again: 3 Stocks That Could Feel the Pain
- Snowflake Could Be Headed for New Highs Despite Insider Selling
- MongoDB Is Surging—And the Next Catalyst Is Almost Here
Receive News & Ratings for Contineum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Contineum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
